Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Iodine Absorption Cells Purity Testing.
Hrabina J, Zucco M, Philippe C, Pham TM, Holá M, Acef O, Lazar J, Číp O. Hrabina J, et al. Among authors: zucco m. Sensors (Basel). 2017 Jan 6;17(1):102. doi: 10.3390/s17010102. Sensors (Basel). 2017. PMID: 28067834 Free PMC article.
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; Italian Migraine Registry study group. Barbanti P, et al. Among authors: zucco m. J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3. J Neurol. 2024. PMID: 38564057 Free PMC article. No abstract available.
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti P, Egeo G, Proietti S, d'Onofrio F, Aurilia C, Finocchi C, Di Clemente L, Zucco M, Doretti A, Messina S, Autunno M, Ranieri A, Carnevale A, Colombo B, Filippi M, Tasillo M, Rinalduzzi S, Querzani P, Sette G, Forino L, Zoroddu F, Robotti M, Valenza A, Camarda C, Borrello L, Aguggia M, Viticchi G, Tomino C, Fiorentini G, Orlando B, Bonassi S, Torelli P; Italian Migraine Registry study group. Barbanti P, et al. Among authors: zucco m. Neurol Ther. 2024 Mar 7. doi: 10.1007/s40120-024-00591-z. Online ahead of print. Neurol Ther. 2024. PMID: 38451463
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; ERT; for the Italian Migraine Registry study group. Barbanti P, et al. Among authors: zucco m. J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17. J Neurol. 2024. PMID: 38231271 Free PMC article.
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
Barbanti P, Egeo G, Aurilia C, Altamura C, d'Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F; Italian Migraine Registry study group. Barbanti P, et al. Among authors: zucco m. J Headache Pain. 2022 Nov 1;23(1):138. doi: 10.1186/s10194-022-01498-6. J Headache Pain. 2022. PMID: 36316648 Free PMC article.
The first report of the Italian Migraine Registry (I-GRAINE).
Barbanti P, Egeo G, Aurilia C, Fiorentini G, Proietti S, Tomino C, Bonassi S; Italian Migraine Registry Study Group. Barbanti P, et al. Neurol Sci. 2022 Sep;43(9):5725-5728. doi: 10.1007/s10072-022-06214-5. Epub 2022 Jul 8. Neurol Sci. 2022. PMID: 35802219
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Barbanti P, et al. Among authors: zucco m. J Headache Pain. 2022 Jun 7;23(1):64. doi: 10.1186/s10194-022-01434-8. J Headache Pain. 2022. PMID: 35672670 Free PMC article. No abstract available.
29 results